← GLP-1 receptor agonists × body weight & composition

TrialDiabetologia2020

Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.

Maurice B Bizino et al.PubMed ↗Full text ↗Publisher ↗

  • Liraglutidelooks good hereLower body weight.Randomised, small.

What the trial testedrandomised · 50 people · 2020

Randomised vs placebo

Probably lowered body weight

−4.50−6.40 to −2.60

liraglutide vs placebo

As reported

difference −4.5, 95% CI −6.40 to −2.60

Range includes no effect

No clear effect on liver & MASLD

+0.03−0.09 to +0.04

As reported

difference 0.03, 95% CI −0.09 to 0.04

Who was studied, and how

50people with type 2 diabetes, in this paper

The trial randomly assignedassigned by chance

liraglutide
placebo

Probably lowered body weight−4.50

randomised

the abstract, start to end

… (estimated mean treatment effect 0.03 [95% CI -0.09, 0.04], p …

… kg; estimated treatment effect -4.5 [95% CI -6.4, -2.6] kg).

← favours treatmentfavours comparator →
could be chance
Liver & masld
0.03−0.09 to 0.04
Body weightliraglutide vs placebo
−4.5−6.40 to −2.60
GLP-1 receptor agonistsBody weight & compositionLiver & MASLD

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.900.90 without it

GLP-1 receptor agonists × liver & masldhelps?one trial

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 6

63 papers cite itlatest 60 shown

2020
…
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT01761318phase 450 enrolled2013
Full record →Abstract, authors, funding and every citing paper · PMID 31690988